Spectral AI (MDAI) Aktienübersicht
Spectral AI, Inc. ist ein Unternehmen für künstliche Intelligenz (KI), das sich auf prädiktive medizinische Diagnostik in den Vereinigten Staaten konzentriert. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 0/6 |
| Dividenden | 0/6 |
MDAI Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$5
FV
70.0% unterbewertet intrinsischer Abschlag535
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Spectral AI, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$1.50 |
| 52-Wochen-Hoch | US$2.97 |
| 52-Wochen-Tief | US$1.18 |
| Beta | 1.17 |
| 1 Monat Veränderung | -11.24% |
| 3 Monate Veränderung | -26.83% |
| 1 Jahr Veränderung | -39.02% |
| 3 Jahre Veränderung | -85.88% |
| 5 Jahre Veränderung | -84.50% |
| Veränderung seit IPO | -84.54% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 28
MDAI: Burn Imaging Clearance Will Drive Next Phase Of Commercial Adoption
Analysts have adjusted their price target for Spectral AI to $4, citing the recent FDA De Novo clearance and the planned commercial rollout of the DeepView System as key drivers of their updated view. Analyst Commentary Recent research updates on Spectral AI have centered on the impact of FDA De Novo clearance for the DeepView System and what it could mean for the company’s next phase.Narrative-Update • Jul 13
MDAI: FDA Burn Clearance Will Support Future Burn Care Commercial Adoption
Analysts have lifted their price target on Spectral AI stock to $4, up from $3, citing the recent FDA clearance of the DeepView System as a key driver of their updated outlook. What’s in the News for Spectral AI Spectral AI received De Novo Classification from the U.S. Food and Drug Administration for its DeepView System, authorizing commercial distribution in the United States for burn care use in burn centers, trauma centers, and emergency departments.Narrative-Update • Jun 17
MDAI: FDA Burn Care Clearance Will Drive Future Commercialization Potential
Spectral AI's analyst price target has moved from $3 to $4, with analysts highlighting the recent FDA clearance of the DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key factor in their updated view. What’s in the News for Spectral AI The U.S. FDA has granted De Novo Classification for Spectral AI’s DeepView System, authorizing commercial distribution for burn care use in burn centers, trauma centers, and emergency departments.
Narrative-Update • Jun 03
MDAI: FDA Clearance And BARDA Funding Will Support Future Burn Preparedness
Spectral AI's analyst price target has increased by $1 to $4, with analysts citing the recent FDA clearance of its DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key driver of the reassessment. What's in the News U.S. FDA granted De Novo Classification for Spectral AI's DeepView System, authorizing commercial distribution for burn care in burn centers, trauma centers, and emergency departments.Recent updates
Narrative-Update • Jul 28
MDAI: Burn Imaging Clearance Will Drive Next Phase Of Commercial Adoption
Analysts have adjusted their price target for Spectral AI to $4, citing the recent FDA De Novo clearance and the planned commercial rollout of the DeepView System as key drivers of their updated view. Analyst Commentary Recent research updates on Spectral AI have centered on the impact of FDA De Novo clearance for the DeepView System and what it could mean for the company’s next phase.Narrative-Update • Jul 13
MDAI: FDA Burn Clearance Will Support Future Burn Care Commercial Adoption
Analysts have lifted their price target on Spectral AI stock to $4, up from $3, citing the recent FDA clearance of the DeepView System as a key driver of their updated outlook. What’s in the News for Spectral AI Spectral AI received De Novo Classification from the U.S. Food and Drug Administration for its DeepView System, authorizing commercial distribution in the United States for burn care use in burn centers, trauma centers, and emergency departments.Narrative-Update • Jun 17
MDAI: FDA Burn Care Clearance Will Drive Future Commercialization Potential
Spectral AI's analyst price target has moved from $3 to $4, with analysts highlighting the recent FDA clearance of the DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key factor in their updated view. What’s in the News for Spectral AI The U.S. FDA has granted De Novo Classification for Spectral AI’s DeepView System, authorizing commercial distribution for burn care use in burn centers, trauma centers, and emergency departments.Narrative-Update • Jun 03
MDAI: FDA Clearance And BARDA Funding Will Support Future Burn Preparedness
Spectral AI's analyst price target has increased by $1 to $4, with analysts citing the recent FDA clearance of its DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key driver of the reassessment. What's in the News U.S. FDA granted De Novo Classification for Spectral AI's DeepView System, authorizing commercial distribution for burn care in burn centers, trauma centers, and emergency departments.
Narrative-Update • May 24
Spectral AI (MDAI): DeepView AI Automated Wound Imaging System Granted FDA Approval!!!
Well this is the news I and many others have been waiting ten months for, and certainly in my case expecting given the information in the public domain… the first of its kind automated wound imaging and assessment device has been granted US FDA approval!!! Years of work by the dedicated team at Spectral AI and partners such as the US Government’s BARDA have put this relatively small company on the map, with a device that offers burn specialists and clinicians the opportunity to potentially improve patient outcomes and hopefully save time and money for all concerned.Analyseartikel • May 15
Analyst Estimates: Here's What Brokers Think Of Spectral AI, Inc. (NASDAQ:MDAI) After Its First-Quarter Report
The analysts might have been a bit too bullish on Spectral AI, Inc. ( NASDAQ:MDAI ), given that the company fell short...Narrative-Update • May 08
MDAI: BARDA Funding And New Leadership Will Support Future Burn Preparedness
Analysts have trimmed their price target on Spectral AI to $6.00, reflecting slightly lower profit margin assumptions and a higher forward P/E multiple, even though their fair value estimate remains at $6.00 and discount rate expectations have eased. What's in the News Spectral AI received $31.7 million in immediate, non dilutive funding from the Biomedical Advanced Research and Development Authority to support additional feature development for its DeepView System, alongside a commitment from the company to contribute $9.7 million to total development costs (BARDA contract 75A50123C00049).Narrative-Update • Apr 21
MDAI: BARDA Funding And New Leadership Will Support Future Commercialization Potential
Analysts have updated their price targets on Spectral AI to reflect revised assumptions for discount rates, revenue growth, profit margins, and a higher forward P/E. These changes have resulted in a revised assessment of the potential upside in the shares.Narrative-Update • Apr 06
MDAI: BARDA Funding And Leadership Transition Will Support Future Burn Preparedness
Analysts have nudged their Spectral AI price target to $6.00, citing small adjustments to assumptions on discount rate, revenue trends, profit margins, and a very high future P/E multiple as key drivers of the updated view. What's in the News Spectral AI received $31.7 million in immediate, non dilutive funding from the Biomedical Advanced Research and Development Authority to support additional feature development for its DeepView System, an AI driven burn wound imaging technology, alongside a company commitment of $9.7 million to total development costs (BARDA contract 75A50123C00049).Analyseartikel • Mar 27
News Flash: Analysts Just Made A Stunning Upgrade To Their Spectral AI, Inc. (NASDAQ:MDAI) Forecasts
Shareholders in Spectral AI, Inc. ( NASDAQ:MDAI ) may be thrilled to learn that the analysts have just delivered a...Narrative-Update • Mar 23
MDAI: BARDA Funding Will Support Future Burn Preparedness Commercialization Potential
Analysts have trimmed their price target on Spectral AI from $7.45 to $6.00 as they now apply a higher discount rate, expect a 28.16% decline in revenue growth, see profit margins at 12.86%, and use a much higher forward P/E multiple of 254.14x in their models. What's in the News Spectral AI received $31.7 million in immediate, non-dilutive funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to accelerate additional features for its DeepView System, with the company committing a further $9.7 million of its own capital to the project (Key Developments).Narrative-Update • Mar 09
MDAI: New CEO Appointment Will Support Future Margin Recovery Potential
Analysts have trimmed their Spectral AI price target to $3.00, citing slightly higher discount rates, softer revenue growth expectations, a lower projected profit margin, and a higher assumed future P/E multiple in their updated model. What's in the News Spectral AI appointed Vincent S.Narrative-Update • Feb 23
MDAI: Leadership Transition And Commercialization Progress Will Support Future Margin Recovery
Narrative Update on Spectral AI Analysts have kept their Spectral AI price target steady at $3.00, with unchanged fair value assumptions and only small tweaks to the discount rate, revenue growth, profit margin, and future P/E inputs. These adjustments support a largely unchanged outlook.Neues Narrative • Feb 14
Spectral AI: First of Its Kind Automated Wound Healing Prediction
Overview Spectral AI is an artificial intelligence business offering predictive wound diagnostics designed to facilitate faster and more accurate treatment decisions in wound care. Spectral’s shares are traded as NASDAQ: MDAI.Narrative-Update • Feb 07
MDAI: Contract Timing Shift Will Support Future Margin Recovery And Revenue Upside
Analysts have adjusted their price target on Spectral AI to reflect a slightly lower discount rate, a small change in expected revenue contraction, and an updated future P/E of about 86x, while keeping fair value steady at US$3.00. What's in the News Spectral AI revised its earnings guidance for fiscal year 2025, reducing expected revenue guidance from US$21.5 million to US$18.5 million.Analyseartikel • Jan 27
Spectral AI, Inc. (NASDAQ:MDAI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Narrative-Update • Jan 23
MDAI: Contract Timing Shift Will Support Future Margin And Revenue Upside
Analysts now estimate Spectral AI's fair value at US$3.00 per share, unchanged from the prior US$3.00 view, as minor adjustments to the discount rate, revenue outlook, profit margin and future P/E assumptions leave their overall price target the same. What's in the News Spectral AI revised its revenue guidance for fiscal 2025 to US$18.5 million from US$21.5 million, reflecting updated expectations for the year (company guidance).Narrative-Update • Jan 08
MDAI: Future Contract Timing Shift Will Support Stronger Profit Margins
Analysts have trimmed their price targets on Spectral AI to US$3.00, pointing to updated assumptions that include a slightly higher discount rate, a smaller revenue decline, a higher profit margin outlook, and a lower future P/E multiple of about 88x. What's in the News Spectral AI reduced its revenue guidance for fiscal 2025 from US$21.5 million to US$18.5 million, citing timing of work on its BARDA contract and effects from the current US government shutdown (Key Developments).Narrative-Update • Dec 14
MDAI Future Revenue Shift From Contracts Will Support Stronger Profit Margins
Analysts have trimmed their price target on Spectral AI to reflect a modestly lower fair value estimate of 3.0 dollars from 3.5 dollars. They cited slightly higher perceived risk, even as outlooks improve for revenue contraction and profit margins, along with a marginally more attractive future earnings multiple.Analyseartikel • Nov 28
Spectral AI, Inc. (NASDAQ:MDAI) Shares Could Be 26% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Spectral AI fair value estimate is US$2.14 Current share price...Analyseartikel • Nov 28
The Market Doesn't Like What It Sees From Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Yet As Shares Tumble 27%
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders won't be pleased to see that the share price has had a very rough month...Analyseartikel • Oct 23
At US$2.24, Is Spectral AI, Inc. (NASDAQ:MDAI) Worth Looking At Closely?
Spectral AI, Inc. ( NASDAQ:MDAI ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively...Analyseartikel • Sep 06
Market Cool On Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Pushing Shares 25% Lower
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders won't be pleased to see that the share price has had a very rough month...Analyseartikel • Aug 16
Spectral AI, Inc. (NASDAQ:MDAI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.09
NasdaqCM:MDAI 1 Year Share Price vs Fair Value Explore Spectral AI's Fair Values from the Community and select yours...Analyseartikel • Jul 29
Estimating The Intrinsic Value Of Spectral AI, Inc. (NASDAQ:MDAI)
Key Insights The projected fair value for Spectral AI is US$2.91 based on 2 Stage Free Cash Flow to Equity Spectral...Analyseartikel • Jun 22
The Market Lifts Spectral AI, Inc. (NASDAQ:MDAI) Shares 50% But It Can Do More
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders have had their patience rewarded with a 50% share price jump in the last...Analyseartikel • Jun 22
The Market Lifts Spectral AI, Inc. (NASDAQ:MDAI) Shares 50% But It Can Do More
The Spectral AI, Inc. ( NASDAQ:MDAI ) share price has done very well over the last month, posting an excellent gain of...
Neues Narrative • May 06
FDA Submission Success Will Advance DeepView Global Opportunities
Successful burn validation study and international expansion strengthen FDA submission, potentially accelerating approval and driving future revenue growth.Analyseartikel • Mar 08
Take Care Before Jumping Onto Spectral AI, Inc. (NASDAQ:MDAI) Even Though It's 28% Cheaper
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders that were waiting for something to happen have been dealt a blow with a...Analyseartikel • Feb 10
Estimating The Intrinsic Value Of Spectral AI, Inc. (NASDAQ:MDAI)
Key Insights Spectral AI's estimated fair value is US$2.15 based on 2 Stage Free Cash Flow to Equity With US$2.06 share...Analyseartikel • Dec 18
Investors Still Aren't Entirely Convinced By Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Despite 39% Price Jump
Despite an already strong run, Spectral AI, Inc. ( NASDAQ:MDAI ) shares have been powering on, with a gain of 39% in...Aktionärsrenditen
| MDAI | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -10.2% | 7.3% | -2.6% |
| 1Y | -39.0% | -15.9% | 14.3% |
Rendite im Vergleich zur Industrie: MDAI unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -16.9% erzielte.
Rendite vs. Markt: MDAI hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 16 erzielte.
Preisvolatilität
| MDAI volatility | |
|---|---|
| MDAI Average Weekly Movement | 9.6% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: MDAI hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: MDAIDie wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| n/a | 65 | Vince Capone | www.spectral-ai.com |
Spectral AI, Inc. ist ein Unternehmen für künstliche Intelligenz (KI), das sich in den Vereinigten Staaten auf prädiktive medizinische Diagnostik konzentriert. Das Unternehmen bietet das DeepView System an, das mit Hilfe proprietärer KI-Algorithmen zwischen vollständig geschädigten, teilweise geschädigten und gesunden menschlichen Gewebemerkmalen unterscheidet, die zum Zeitpunkt der Wundentstehung mit bloßem Auge nicht erkennbar sind, und eine binäre Vorhersage über die Fähigkeit der Wunde zur Heilung zu einem bestimmten Zeitpunkt in der Zukunft liefert, um den Arzt dabei zu unterstützen, eine genauere, zeitnahe und fundierte Entscheidung über die Behandlung der Wunden des Patienten zu treffen. Das Unternehmen entwickelt auch die AI-Burn-Software und die MSI-Bildgebungstechnologie, die aus proprietären multispektralen Optiken und Sensoren besteht, die Bilder von verletztem Gewebe erfassen.
Spectral AI, Inc.'s Grundlagenzusammenfassung
| MDAI grundlegende Statistiken | |
|---|---|
| Marktanteil | US$49.65m |
| Gewinn(TTM) | -US$13.88m |
| Umsatz(TTM) | US$16.93m |
2.8x
Kurs-Umsatz-Verhältnis-3.4x
Kurs-Gewinn-Verhältnis Ist MDAI zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| MDAI Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$16.93m |
| Kosten der Einnahmen | US$9.15m |
| Bruttogewinn | US$7.78m |
| Sonstige Ausgaben | US$21.66m |
| Gewinn | -US$13.88m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.44 |
| Bruttomarge | 45.97% |
| Nettogewinnspanne | -81.97% |
| Schulden/Eigenkapital-Verhältnis | -95.5% |
Wie hat sich MDAI auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/29 07:13 |
| Aktienkurs zum Tagesende | 2026/07/29 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Spectral AI, Inc. wird von 6 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Michael Gorman | BTIG |
| Carl Byrnes | Northland Capital Markets |
| Lucas John Horton | Northland Capital Markets |